Introducing the D‐ <scp>DAND</scp> scale: Development of a comprehensive caregiver‐administered tool for Dravet syndrome comorbidities

Abstract Objective The Dravet Disease‐Associated Neuropsychiatric Disorders (D‐DAND) scale is a new caregiver‐administered interview designed to assess the wide range of developmental and behavioral comorbidities in Dravet syndrome (DS) beyond seizures. D‐DAND's preliminary psychometric properties in a large patient sample are reported. Methods D‐DAND was developed by a panel of experts and later standardized with caregivers of 123 individuals with DS (age = 3–41 years); a subsample of 43 caregivers were interviewed twice (~2 weeks apart) to evaluate test–retest reliability; another subsample of 80 were also administered with other scales that are widely used despite not being tailored to DS (Vineland Adaptive Behavior Scales, Child Behavior Checklist, Childhood Autism Rating Scale, Behavior Rating Inventory of Executive Function, Sleep Disturbance Scale for Children). Results The D‐DAND captured a broad spectrum of abilities and dysfunctions across multiple functional domains. Test–retest reliability was excellent (overall score: r ≈ .98, median across domains: r ≈ .89), thus allowing for high sensitivity to time‐related changes. As expected, D‐DAND scores showed high correlations with some standardized measures (e.g., Vineland scales) and low correlation with others, suggesting that D‐DAND measures unique, Dravet‐specific features that other, widely used tools fail to detect. Significance D‐DAND is a novel, reliable tool for comprehensive evaluation of DS beyond seizures. It enables systematic tracking of developmental and behavioral issues in DS, facilitating early identification of needs and more personalized, whole‐person care.

Authors

Institutions

Publication Details

Journal
Epilepsia
Published
2026-08-18
DOI
https://doi.org/10.1002/epi.70399
Primary Topic
Epilepsy research and treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Introducing the D‐ DAND scale: Development of a comprehensive caregiver‐administered tool for Dravet syndrome comorbidities

Lisa Ouss, Delphine Breuillard, Francesca Offredi, Rima Nabbout et al.
Epilepsia
Epilepsy research and treatment
article

Introducing the D‐ DAND scale: Development of a comprehensive caregiver‐administered tool for Dravet syndrome comorbidities

Lisa Ouss, Delphine Breuillard, Francesca Offredi, Rima Nabbout, Francesca Darra, Isabella Brambilla, Alessio Toraldo, Tommaso Lo Barco, Mathilde Cozzo, Bernardo Dalla Bernardina
article en

Abstract

Abstract Objective The Dravet Disease‐Associated Neuropsychiatric Disorders (D‐DAND) scale is a new caregiver‐administered interview designed to assess the wide range of developmental and behavioral comorbidities in Dravet syndrome (DS) beyond seizures. D‐DAND's preliminary psychometric properties in a large patient sample are reported. Methods D‐DAND was developed by a panel of experts and later standardized with caregivers of 123 individuals with DS (age = 3–41 years); a subsample of 43 caregivers were interviewed twice (~2 weeks apart) to evaluate test–retest reliability; another subsample of 80 were also administered with other scales that are widely used despite not being tailored to DS (Vineland Adaptive Behavior Scales, Child Behavior Checklist, Childhood Autism Rating Scale, Behavior Rating Inventory of Executive Function, Sleep Disturbance Scale for Children). Results The D‐DAND captured a broad spectrum of abilities and dysfunctions across multiple functional domains. Test–retest reliability was excellent (overall score: r ≈ .98, median across domains: r ≈ .89), thus allowing for high sensitivity to time‐related changes. As expected, D‐DAND scores showed high correlations with some standardized measures (e.g., Vineland scales) and low correlation with others, suggesting that D‐DAND measures unique, Dravet‐specific features that other, widely used tools fail to detect. Significance D‐DAND is a novel, reliable tool for comprehensive evaluation of DS beyond seizures. It enables systematic tracking of developmental and behavioral issues in DS, facilitating early identification of needs and more personalized, whole‐person care.

Epilepsia
University of Verona (IT), Hôpital Necker-Enfants Malades (FR), European Union (BE), Inserm (FR), Université Paris Cité (FR), University of Pavia (IT), Azienda Ospedaliera Universitaria Integrata Verona (IT), Assistance Publique – Hôpitaux de Paris (FR), Neuroscience Institute (IT), Institut des Maladies Génétiques Imagine (FR)
Openalex Percentile: Top 8%
Epilepsy research and treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.